CINYSEThe short version
The Cigna Group
The Cigna Group is a $76.5 billion US health company — one of three national pharmacy-benefit managers bolted to a medical insurer — whose shares fell about a third from their 2024 peak before partly recovering.
Shares peaked at $367 in September 2024, bottomed at $244 in October 2025, and trade at $285 today.
$285
Share price
$76.5B
Market cap
9.8%
Adjusted FCF yield
−33%
Peak-to-trough fall
SwipeScroll▾
The company
A $275 billion health company: pharmacy benefits plus medical insurance
FY2020 → FY2025as reported · $
Revenue$274.9B+11%
Operating margin3.3%−0.5pp
Net income$6.0B+73%
EPS$22.18+83%
Open the full statements →FY2020 to FY2025, as reported.
- Two engines. Evernorth manages the nation's drug spend at scale; Cigna Healthcare insures and administers medical plans. FY2025 revenue was $274.9B, net income $6.0B, adjusted EPS $29.84.
- Priced low. At $284.85 the shares trade at 12.8x FY2025 adjusted EPS and 0.28x sales — the cheapest positive multiple in the large managed-care group.
The fit
Leans toward fitting the framework; watchlist-only: no qualifying long-dated options; contested: P1, P2
Where the pillars land
| Pillar test | Where it sits |
|---|---|
| Year-10 durability (P1) | Contested |
| Adjusted FCF yield | 9.8% vs 10% bar |
| Damage diagnosis | 62% temporary |
| Confidence tier | Low |
- Clears the screen, straddles the bar. Cigna passes the universe test and trips no exclusion. Adjusted FCF yields 9.8% against the 10% bar — 10.9% on the three-year average — and the dislocation, yield, self-help and diagnosis pillars land on the fit side.
- Watchlist, not live. No qualifying long-dated options could be confirmed from a citable source, so the framework's watchlist-only rule applies.
- The gate is contested. Two jurors read year-10 durability as met, two as not-met, and a name-masked probe flipped it: federal PBM reform landing in 2028 caps conviction on the cash-flow leg.
The two engines
A giant thin-margin pharmacy business and a smaller fat-margin insurer
FY2025 pre-tax adjusted income by unit
Cigna Healthcare (insurance)$4.2B36%
Evernorth: Specialty & Care$3.7B33%
Evernorth: Pharmacy Benefits$3.5B31%
Total pre-tax adjusted income $11.4B across the two segments.
- Scale sits in pharmacy; profit density in insurance. Evernorth is 83% of segment revenue but only 64% of segment profit, at a 3.1% margin; Cigna Healthcare earns 8.8%.
- More administrator than risk-taker. Of 18.1M medical members, 79% are self-funded employer plans on which Cigna earns a fee and bears no claims risk.
The valuation
The cheapest name in a sector nobody wants to own
Price / FY2025 earnings
- No consensus darling. At 12.8x earnings Cigna trades below Elevance and far under UnitedHealth — the opposite of a story the whole market already owns.
- The counter. Low price-to-sales is structural for pass-through managed care, so the earnings multiple is the telling gauge; the two dearest peers look elevated only because their 2025 earnings are depressed.
The dislocation
A third of the value gone on datable triggers, not one crash
Four managed-care and pharmacy-benefit legs over 410 days.
- Down 33%. From $366.85 in September 2024 to $244.41 in October 2025 across four datable legs; the shares sit at $284.85 now, still 22% below the peak.
- Fear was moderate. Sustained volume peaked at only 2.12x the pre-drawdown median — short of the 3–5x that marks forced selling — though 30 October 2025 alone traded near 7.4x.
Damage math
The price fell far more than the problem could plausibly cost
Value destroyed, peak to now
- Earnings never broke. Adjusted EPS grew every year of the fall — $25.09 (2023) to $29.84 (2025) — so the ~26% drop from the peak was a multiple re-rating, from about 12x forward earnings to 9x.
- A $19–27B gap. Even a severe permanent PBM re-basing destroys about $8.8B of value against ~$27.5B erased. The counter: if the margin re-bases lower for good, intrinsic value could near today's price.
Temporary or permanent
A blind trial put the odds the damage is temporary at 62%
62%
Trial: probability the damage is temporary
100 bps
Insurance margin to recapture by 2027
−28%
Q1 2026 pharmacy-benefit income (revenue rose 11%)
- Two mechanisms, two fates. The stop-loss miss reprices mechanically each January; the pharmacy-benefit compression is the contested piece, where 2028 rebate reform could re-base margins for good.
- The honest weight. Three independent judges leaned temporary but held roughly 38% on the permanent case — a lean, not a certainty.
Yield vs the bar
Adjusted free cash flow yields near the 10% line, not above it
Adjusted FCF yield
FY2025 trailing
9.8%
3-year average
10.9%
7-year median
10.3%
Consensus forward FY26
11.8%
- A return to norm, not a fear spike. Cigna's adjusted yield has orbited 10% for a decade; the drawdown moved it from about 7% at the peak back toward its own baseline — not the fortress jump the framework prizes.
- Definition matters. On the richer vendor cash-flow line forward yields run 11.8–13.4%; on a plainer cash-from-operations-less-capex build the current year is about 9.1%, just under the bar.
The year-10 gate
Revenue clears with conviction; the cash-flow leg carries a named doubt
Revenue rose every year ($B)
- The easy leg. Revenue rose in all nine yearly steps to $274.9B inside a three-firm pharmacy-benefit oligopoly behind licensing and capital barriers — year-10 revenue higher is a high-conviction claim.
- The doubt. Federal law moves rebate-and-spread economics onto a transparent fee basis by 2028–29, hitting a unit that earned about 31% of pre-tax income; that caps conviction on the cash-flow leg.
Self-help
The share count is down 29% since 2019, and still falling
Shares outstanding (millions)
- Buybacks are real, not just authorized. Cigna spent roughly $37B retiring stock over the decade — $3.6B, $7.0B and $2.3B in 2025/2024/2023 — while stock-based pay is a small $291M.
- Room to keep going. Net debt is 1.8x EBITDA with only $550M due in 2026, and management ranks repurchases ahead of debt paydown. The counter: the buyback cadence is lumpy.
The clock
Comparable drawdowns round-tripped in roughly 11 to 36 months
Top-to-bottom-and-back (months)
- A scheduled mechanism. Stop-loss and exchange books reprice every January; guidance was reset low, then beaten and raised five straight quarters, with the 2026 round tracking in line.
- Running slow so far. This episode has already run about 22 months and sits 22% below the peak — past the name's ~19-month median round trip, tracking the slower end.
What a re-rating needs
Near fair on cash-flow yield; the case rests on the pause proving temporary
10.9%
3-year adjusted yield vs the 10% bar — near fair, not deep
$30→$42
Consensus adjusted EPS, FY2026 to FY2029
~19 mo
Median round-trip in this name's own history
- No deep-yield entry. At a 10.9% mid-cycle yield the $76.5B market cap already sits near fair on the bar, so a re-rating leans on multiple recovery rather than a cheap cash-flow price.
- What the buy side must concede. The sell side already models forward cash flow above the bar and EPS re-accelerating toward $42 by 2029; the setup asks that the 2026 pause is not permanent.
What to watch
The price fell far more than the problem plausibly cost — but the gate is contested and the instruments unconfirmed.
- 01FY2026 Cigna Healthcare MCR above 84.7% or adjusted EPS below $30.25, showing repricing failed.
- 02share count inflects upward
- 03capital allocation pivots to debt paydown over repurchases
- 04Post-2028 PBM profit per claim remains below 2025 levels after rebate-remittance and delinking are fully implemented.
This distills a fixed, tab-by-tab test of one investor's framework — not investment advice.
Compiled from the full report · 2026-07-23 · For information, not investment advice.